Adding the investigational anticancer therapeutic tivantinib to standard erlotinib treatment substantially increased progression-free survival for patients with advanced nonsquamous non–small cell lung cancer (NSCLC) who ...
Nov 9, 2015
0
9
Highly anticipated phase III clinical trial results of Spark Therapeutics's gene therapy to treat visual impairment are due by year-end and could have profound implications for the broader gene therapy field, leading to the ...
Oct 15, 2015
0
7
A new technique developed by statisticians that is helping doctors optimize the dose of a new cancer treatment patients receive in phase I/ II clinical trials was presented today by Juhee Lee, assistant professor of applied ...
Aug 10, 2015
0
19
The phase IIIb CONSIGN study has confirmed the benefit of regorafenib in patients with previously treated metastatic colorectal cancer (mCRC), researchers announced at the ESMO 17th World Congress on Gastrointestinal Cancer ...
Jul 3, 2015
0
15
In a first for HIV prevention, an international team of researchers have completed follow-up of participants enrolled in a pivotal Phase III trial that tested the safety and effectiveness of a vaginal ring for preventing ...
Jun 29, 2015
0
45
A recently published clinical trial report reviewing the first completed Phase III study in the ODYSSEY development program has shown that alirocumab showed significantly better LDL-C lowering than ezetimibe, with a comparable ...
Feb 17, 2015
0
11
Results from a trial of the anti-cancer drug galeterone show that it is successful in lowering prostate-specific antigen (PSA) levels in men with a form of prostate cancer that is resistant to treatment with hormone therapy ...
Nov 18, 2014
0
0
The I-SPY 2 trial identified a neo-adjuvant regimen containing the investigational drug neratinib and standard chemotherapy to be beneficial for hormone receptor (HR)-negative, HER2-positive primary (non-metastatic) breast ...
Apr 8, 2014
0
0
The drug palbociclib, an inhibitor of cyclin-dependent kinases (CDK) 4 and 6, significantly improved progression-free survival when administered as a first-line treatment in patients with hormone receptor-positive, metastatic ...
Apr 7, 2014
0
0
Treatment with the bisphosphonate zoledronate did not improve outcomes for women with chemoresistant breast cancer, according to initial results of a phase III clinical trial presented here at the 2013 San Antonio Breast ...
Dec 13, 2013
0
0
